FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973239436> ?p ?o ?g. }

• W1973239436 endingPage "53" @default.
• W1973239436 startingPage "43" @default.
• W1973239436 abstract "While emotional symptoms such as depressed mood and loss of interest have traditionally been considered to constitute the core symptoms of major depressive disorder (MDD), the prevalence and importance of painful physical symptoms such as back pain, abdominal pain, and musculoskeletal pain is becoming increasingly appreciated. Antidepressants possessing dual serotonin/norepinephrine (5-HT/NE) reuptake inhibition may demonstrate greater efficacy in the alleviation of pain. The efficacy of duloxetine, a balanced and potent dual reuptake inhibitor of 5-HT and NE, was evaluated within a cohort of depressed patients with associated painful physical symptoms.In this multicenter, double-blind, placebo-controlled study, patients meeting DSM-IV criteria for MDD were randomized to receive placebo (N=141) or duloxetine 60 mg QD (N=141). Patients were required to have a 17-item Hamilton Rating Scale for Depression (HAMD17) total score 15, a Clinical Global Impression of Severity (CGI-S) score 4, and a Brief Pain Inventory (BPI) Average Pain score 2 at baseline. The primary efficacy measure was the BPI Average Pain score, while secondary measures included other BPI items, the HAMD17 total score, CGI-S, the Patient Global Impression of Improvement (PGI-I) scale, Visual Analog Scales (VAS) for pain, and the Symptom Questionnaire, Somatic Subscale (SQSS). Safety was evaluated by recording treatment-emergent adverse events (spontaneously reported), vital signs, and laboratory analytes.Mean changes in BPI Average Pain for duloxetine- and placebo-treated patients differed significantly at most visits, but only approached significance at endpoint p=0.066. For the main effect of treatment (pooling all visits), significant advantages for duloxetine-treated patients were found in 10 of 11 assessed BPI pain severity and pain interference items, in addition to VAS overall pain and back pain. Mean changes in pain measures for duloxetine-treated patients corresponded to improvements of 25-50%, compared with 19-39% for placebo. Mean changes at endpoint in depression rating scales (HAMD17, CGI-S, PGI-I) did not differ significantly between duloxetine and placebo treatment groups due to unusually high placebo response. The magnitude of placebo treatment effects (as measured by HAMD17 total score and Maier subscale) was significantly smaller in patients with 1 previous depressive episode, compared to those patients with no previous episodes. In patients with 1 previous depressive episode the advantage of duloxetine over placebo was similar to previous studies. Rates of discontinuation due to adverse events were 14.2% vs. 2.1% for duloxetine and placebo, respectively p<0.001. Treatment-emergent adverse events reported at a significantly higher rate by duloxetine-treated patients included nausea, dry mouth, fatigue, and decreased appetite.In this study, duloxetine (60 mg QD) was shown to be an effective treatment for the painful physical symptoms which are frequently associated with depression. Improvements in pain severity occurred independently of changes in depressive symptom severity." @default.
• W1973239436 created "2016-06-24" @default.
• W1973239436 creator A5019090648 @default.
• W1973239436 creator A5042304299 @default.
• W1973239436 creator A5056450962 @default.
• W1973239436 creator A5070367435 @default.
• W1973239436 creator A5084504626 @default.
• W1973239436 creator A5091578640 @default.
• W1973239436 date "2005-01-01" @default.
• W1973239436 modified "2023-10-09" @default.
• W1973239436 title "Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder" @default.
• W1973239436 cites W16441074 @default.
• W1973239436 cites W187953383 @default.
• W1973239436 cites W1961097431 @default.
• W1973239436 cites W1967378279 @default.
• W1973239436 cites W1971393265 @default.
• W1973239436 cites W1972365490 @default.
• W1973239436 cites W1973952980 @default.
• W1973239436 cites W1974376547 @default.
• W1973239436 cites W1977911389 @default.
• W1973239436 cites W1979917573 @default.
• W1973239436 cites W1982721912 @default.
• W1973239436 cites W1987084291 @default.
• W1973239436 cites W2001706056 @default.
• W1973239436 cites W2003049372 @default.
• W1973239436 cites W2003363634 @default.
• W1973239436 cites W2018425549 @default.
• W1973239436 cites W2021189780 @default.
• W1973239436 cites W2028133701 @default.
• W1973239436 cites W2037571119 @default.
• W1973239436 cites W2048361493 @default.
• W1973239436 cites W2048628544 @default.
• W1973239436 cites W2048741804 @default.
• W1973239436 cites W2050707182 @default.
• W1973239436 cites W2057621238 @default.
• W1973239436 cites W2065846769 @default.
• W1973239436 cites W2071535163 @default.
• W1973239436 cites W2073155558 @default.
• W1973239436 cites W2078273189 @default.
• W1973239436 cites W2080747491 @default.
• W1973239436 cites W2083991574 @default.
• W1973239436 cites W2091061257 @default.
• W1973239436 cites W2099564543 @default.
• W1973239436 cites W2114613490 @default.
• W1973239436 cites W2124613380 @default.
• W1973239436 cites W2147464017 @default.
• W1973239436 cites W2152769424 @default.
• W1973239436 cites W2168305909 @default.
• W1973239436 cites W2169741270 @default.
• W1973239436 cites W2183515675 @default.
• W1973239436 cites W2468424440 @default.
• W1973239436 cites W2946556809 @default.
• W1973239436 cites W33374171 @default.
• W1973239436 cites W4211082467 @default.
• W1973239436 cites W4238350088 @default.
• W1973239436 cites W4243811279 @default.
• W1973239436 cites W4244103373 @default.
• W1973239436 cites W4246597319 @default.
• W1973239436 doi "https://doi.org/10.1016/j.jpsychires.2004.04.011" @default.
• W1973239436 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15504423" @default.
• W1973239436 hasPublicationYear "2005" @default.
• W1973239436 type Work @default.
• W1973239436 sameAs 1973239436 @default.
• W1973239436 citedByCount "166" @default.
• W1973239436 countsByYear W19732394362012 @default.
• W1973239436 countsByYear W19732394362013 @default.
• W1973239436 countsByYear W19732394362014 @default.
• W1973239436 countsByYear W19732394362015 @default.
• W1973239436 countsByYear W19732394362016 @default.
• W1973239436 countsByYear W19732394362017 @default.
• W1973239436 countsByYear W19732394362018 @default.
• W1973239436 countsByYear W19732394362019 @default.
• W1973239436 countsByYear W19732394362020 @default.
• W1973239436 countsByYear W19732394362022 @default.
• W1973239436 countsByYear W19732394362023 @default.
• W1973239436 crossrefType "journal-article" @default.
• W1973239436 hasAuthorship W1973239436A5019090648 @default.
• W1973239436 hasAuthorship W1973239436A5042304299 @default.
• W1973239436 hasAuthorship W1973239436A5056450962 @default.
• W1973239436 hasAuthorship W1973239436A5070367435 @default.
• W1973239436 hasAuthorship W1973239436A5084504626 @default.
• W1973239436 hasAuthorship W1973239436A5091578640 @default.
• W1973239436 hasConcept C118552586 @default.
• W1973239436 hasConcept C126322002 @default.
• W1973239436 hasConcept C139719470 @default.
• W1973239436 hasConcept C14184104 @default.
• W1973239436 hasConcept C142724271 @default.
• W1973239436 hasConcept C15744967 @default.
• W1973239436 hasConcept C162324750 @default.
• W1973239436 hasConcept C1862650 @default.
• W1973239436 hasConcept C197934379 @default.
• W1973239436 hasConcept C204787440 @default.
• W1973239436 hasConcept C27081682 @default.
• W1973239436 hasConcept C2776000289 @default.
• W1973239436 hasConcept C2776867660 @default.
• W1973239436 hasConcept C2779177272 @default.
• W1973239436 hasConcept C2780051608 @default.
• W1973239436 hasConcept C2780052408 @default.

• next